These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22621634)

  • 1. Ruxolitinib for myelofibrosis.
    Koschmieder S; Koppelle A; Seifert H
    N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib for myelofibrosis.
    Haznedaroglu IC
    N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruxolitinib for myelofibrosis.
    Diamantidis MD
    N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.
    Tefferi A
    N Engl J Med; 2012 Mar; 366(9):844-6. PubMed ID: 22375977
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
    Reilly JT; McMullin MF; Beer PA; Butt N; Conneally E; Duncombe AS; Green AR; Mikhaeel G; Gilleece MH; Knapper S; Mead AJ; Mesa RA; Sekhar M; Harrison CN
    Br J Haematol; 2014 Nov; 167(3):418-20. PubMed ID: 24961987
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verruconis gallopava in a patient with myelofibrosis on ruxolitinib.
    Hsu A; Ulici V
    Blood; 2020 Apr; 135(14):1189. PubMed ID: 32243521
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
    Barba P; Fox ML; Blanco A; Valcárcel D
    Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
    [No Abstract]   [Full Text] [Related]  

  • 11. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
    Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
    Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
    Gisslinger H; Schalling M; Gisslinger B; Skrabs C; Müllauer L; Kralovics R
    Am J Hematol; 2014 Mar; 89(3):344-6. PubMed ID: 24273107
    [No Abstract]   [Full Text] [Related]  

  • 16. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
    Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
    Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.